Casi pharmaceuticals, inc. (CASI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Product sales

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease income

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product sales

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

23

47

71

71

47

23

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

669

669

669

669

1,932

1,932

1,940

1,940

0

0

0

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Total revenues

7,537

4,131

2,787

0

0

0

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,940

0

0

0

-

-

Costs and expenses:
Costs of revenues

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

0

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

16

16

13

7

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

8,243

7,595

4,997

5,040

4,676

4,645

4,440

4,368

4,229

4,075

3,814

3,569

3,070

2,765

2,535

2,618

2,730

2,677

2,617

2,460

2,320

2,375

2,286

2,366

2,620

3,457

4,343

4,650

0

0

0

General and administrative

25,684

27,336

26,415

25,343

22,403

17,997

13,445

7,166

3,815

3,156

3,379

3,430

4,654

4,775

4,018

4,015

2,958

3,118

3,279

3,755

3,789

3,756

3,688

3,200

3,324

3,063

2,843

2,745

2,331

2,797

2,784

2,776

2,895

3,051

3,221

3,435

0

0

0

Selling and marketing

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Gain) loss on disposal of intangible assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

0

-

5,848

5,848

0

-

686

686

686

0

0

0

0

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

0

Total cost and expenses

54,941

51,089

46,585

41,867

31,828

27,191

23,212

16,098

12,745

10,751

8,377

8,471

9,330

9,420

8,456

8,381

7,187

7,200

7,110

27,023

26,555

26,211

25,905

5,819

6,055

5,740

5,460

5,206

4,651

5,173

5,071

5,143

5,515

6,508

7,564

11,086

0

0

0

Loss from operations

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-operating income/(expense):
Interest income, net

1,203

1,062

792

389

82

40

32

20

7

1

-3

-8

-17

-26

-31

-50

-66

-81

-97

-75

-51

-26

-1

1

1

1

1

-9,164

0

-

0

0

-

-

-

-

-

-

-

Foreign exchange gains

1,109

817

1,269

550

71

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of investment in equity securities

348

288

608

504

364

320

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-45,435

-45,362

-42,344

-41,431

-32,040

-27,471

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: (loss)/ income attributable to redeemable noncontrolling interest

-518

-395

52

75

14

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redeemable noncontrolling interest redemption value

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent rights

-

-

-

-

-

-

-

-

-

19

15

-4

11

6

-5

-38

-32

-27

-35

6

-4

-11

6

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest (income) expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

875

0

106

275

0

0

0

Other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

3

58

0

0

0

Net loss attributable to CASI Pharmaceuticals, Inc.

-46,296

-46,032

-42,400

-41,510

-32,057

-27,471

-23,254

-16,112

-12,660

-10,770

-8,396

-8,476

-9,359

-9,453

-8,482

-8,393

-7,197

-7,206

-7,100

-27,033

-26,554

-26,202

-25,914

-5,817

-6,053

-5,738

-4,790

-4,535

-13,147

-14,545

-13,180

-13,300

-4,495

-4,558

-7,658

-11,294

0

0

0

Dividends on Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

335

586

837

1,005

1,005

1,005

1,005

0

0

0

Net loss attributable to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,880

-13,766

-14,138

-5,500

-5,563

-8,663

-12,299

0

0

0

Net loss per share (basic and diluted) (in dollars per share)

-0.09

-0.13

-0.10

-0.16

-0.09

-0.10

-0.10

-0.07

-0.05

-0.08

-0.03

-0.04

-0.03

-0.02

-0.03

-0.08

-0.04

-0.05

-0.05

-0.06

-0.06

-0.04

-0.77

-0.06

-0.05

-0.05

-0.05

-0.07

-0.05

0.06

-0.05

-0.56

-0.23

0.08

-0.13

-0.17

-0.25

-0.24

-0.57

Weighted average number of common shares outstanding (basic and diluted)

98,773

192,329

95

95,717

95,650

181,676

86

86,029

71,215

65,466

60,196

60,196

60,196

91,135

49,227

42,906

40,207

32,445

32,445

32,445

32,445

32,496

27,804

27,040

27,040

27,090

27,031

27,023

23,357

22,579

22,503

18,979

12,158

-

12,004

11,506

-

-

-

Comprehensive loss:
Net loss

-45,435

-45,362

-42,344

-41,431

-32,040

-27,471

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-46,296

-46,032

-42,400

-41,510

-32,057

-27,471

-23,254

-16,112

-12,660

-10,770

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency translation adjustment

-2,639

-1,501

-2,638

-1,487

-1,442

-1,227

-1,224

-539

527

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-48,074

-46,863

-44,983

-42,919

-33,482

-28,698

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: Comprehensive (loss)/income attributable to redeemable noncontrolling interest

-518

-395

52

75

14

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to common stockholders

-47,556

-46,468

-45,036

-42,995

-33,496

-28,698

-24,479

-16,651

-12,133

-10,770

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding (basic and diluted) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,444

-

-

Weighted average number of shares outstanding (basic and diluted)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,837

9,120